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Background: Western Asia comprises a large proportion of the world population with different ethnicities and religions
inhabiting areas of diverse geographic features. The countries of this region have experienced rapid economic growth over the
latter half of the 20th century, which continues to this day, resulting in major changes in lifestyle of the population.
Objectives: The aim of this study was to compare the incidence and mortality of cancer in West Asia using the estimates
reported by the International Agency for Research on Cancer (IARC) in Globocan-2012.
Methods: Countries with high-quality data or national data (based on the definition of the Globocan-2012) were included in
the analysis. These included Bahrain, Iran, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, and Turkey. We also found
high-quality cancer data from regional cancer registries in 3 Iranian and 3 Turkish provinces. Data on cancer incidence and
mortality were collected and described in tables and graphs. Spearman’s correlation test was used to assess the correlation
between geographic coordinates and the incidence age-standardized rate (ASR; per 100,000 person-years) of cancers.
Findings: Nine countries and 6 regional registries were included. Cancers of the lung (ASR, 33.3), prostate (24.9), bladder
(19.1), stomach (16.5), and colorectal (15.9) were the most common malignancies in men. The most common cancers in women
were those of the breast (35.4), colorectal (12.1), thyroid (10.3), stomach (9.2), and lung (6.7). The incidence rates of upper
gastrointestinal and lung cancers were considerably higher in the northern part of this region, including Turkey and northern
Iran compared with southern countries. High incidences of breast, colorectal, prostate, and bladder cancers were found in
countries located in the northwest including Jordan, Lebanon, and Turkey.
Conclusions: The most common cancers differed by country. Consequently, cancer control programs must be tailored to the
most common types of cancers in each country. Lack of high-quality data for some West Asian countries was the major limitation
of this study. Therefore, as the first step of cancer control programs, it is recommended that well-structured population-based
cancer registries be established in all of these countries.
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Along with improvement of hygiene and the subsidence
of infectious diseases, cancers have emerged as the
leading cause of death in the developed world and the
second most common cause of death in developing
countries. It is expected that cancers continue to hold
this dominant position as the population of the world14-9996/ª 2014 Icahn School of Medicine at Mount Sinai
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p://dx.doi.org/10.1016/j.aogh.2014.09.012continues to age gradually and lifestyle-related factors
(tobacco use, sedentary lifestyle, unhealthy diets, etc.)
prevail. According to the last report of the Globocan
project, there were 14.1 million new cancer cases, 8.2
million cancer deaths, and 32.6 million individuals
living with cancer worldwide in 2012.1 Eight million
(57%) new cancer cases, 5.3 million (65%) cancer
deaths, and 15.6 million (48%) of the 5-year prevalent
cancer cases occurred in the less-developed regions.1 In
other words, the developing world is bearing more than
half of the worldwide cancer burden.
West Asia comprises a multitude of low- and
middle-income countries (LMICs). It is home to a large
proportion of the world population with different
ethnicities and religions inhabiting areas of diverse
geographic features. The countries of this region experi-
enced rapid economic growth over the latter half of the
Anna l s o f G l o b a l Hea l t h 34720th century, which continues to this day, resulting in
major changes in lifestyle of the population. In this study,
we aim to compare the incidence and mortality of cancer
in West Asia using the estimates reported by the Inter-
national Agency for Research on Cancer (IARC).1METHODS
Sources of Cancer Data
We mainly used the Globocan-2012 data for analyzing
cancer incidence, prevalence, and mortality.1 Only coun-
tries with high-quality data or national data (categories A, B,
C, and D of the Globocan-2012 classification) were
included. The quality of data in Globocan-2012 was
assessed and classified according to the indices of data
quality used in the Cancer in Five Continents X.2 These
included the percentage of cases microscopically verified
(MV%), the percentage of cases registered from a death
certificate only (DCO%), the proportion of unknown basis
of diagnosis (UB%), and the ratio of the number of deaths
from a particular cancer to the number of cases registered
during the same period (MI%). We also explored the
Cancer in Five Continents X website2 to find cancer data
from high-quality regional or provincial cancer registries
(according to the aforementioned criteria) from this region.
Selected Countries
We aimed to analysis cancer data from countries in West
Asia. High-quality data or national data were available for
only 9 of the West Asian countries in Globocan-2012,
including Bahrain, Iran, Jordan, Kuwait, Lebanon,Figure 1. West Asian countries for which high-quality or national
presented as a (A) map and (B) graph.Oman, Qatar, Saudi Arabia, and Turkey.1 Cancer data
from these countries were collected and included in our
final analysis (Fig. 1).
Regional Registries
High-quality cancer data was found from regional cancer
registries in 6 provinces of Iran and Turkey. These
included Golestan (Northeast), Ardabil (Northwest), and
Kerman (South) provinces of Iran, as well as Trabzon
(Northeast), Edirne (Northwest), and Antalya (South) in
Turkey (Fig. 1).
Statistical Analysis
Data on the incidence age-standardized rate (ASR; per
100,000 person-years), 5-year prevalence of cancers
(proportion per 100,000), as well as the ASR and cu-
mulative risk (%, age 0-74) of cancer mortality were
collected. The pooled ASRs of cancers for all 9 included
countries were extracted from the Globocan-2012 data
set1 Using the pooled ASRs, we identified the most
common cancers in West Asian men and women.
Considering the historical importance of esophageal
cancer in northern Iran,3,4 the distribution of esophageal
cancer also was presented. Tables and graphs were
created to describe the data.
To show the geographic distribution of cancers
in graphs, the countries and provinces were ordered
according to their geographic latitude and longitude.
Spearman’s correlation test was used to assess the
correlation between geographic coordinates and the
ASRs of cancers. P < .05 was considered significant.data on cancers was available in the Globocan-2012 project,
Table 1. Incidence ASR (per 100,000 person-years) and 5-y prevalence (P) (proportion per 100,000) of Cancers Incidence in West Asia, Male
Bahrain Iran Jordan Kuwait Lebanon Oman Qatar
Saudi
Arabia Turkey Pooled
ASR P ASR P ASR P ASR P ASR P ASR P ASR P ASR P ASR P ASR P
Lip, oral cavity 3.2 4.2 2.2 5.7 2.2 4.7 1.5 4.1 2.6 7.1 1.9 4 2 4.8 2 3.9 2.7 7.5 2.4 6
Nasopharynx 0.2 1.1 0.8 2.6 1.3 3.2 0.4 1.5 1.1 3.7 0.5 1.5 0.8 2.2 1.7 4.9 1.6 5.6 1.2 4
Other pharynx 0.8 0 0.4 1 0.3 0.8 0.1 0.2 0.5 1.5 0.5 1.1 0.7 0.5 0.4 0.8 0.9 2.7 0.6 1.6
Esophagus 2.2 1 9 8.7 1.2 1 0.7 0.8 0.9 1 1.8 1 1.8 0.9 1.4 0.9 4.3 4.6 5.6 5.2
Stomach 4.5 3.5 20.6 27.9 6.5 8.1 2.8 4.6 6.5 11 6.4 5.1 6 5.6 3.8 3.8 17.9 27.6 16.5 21.9
Colorectal 11.8 18.8 11.6 27.5 29.8 55.9 12.6 26.7 19.1 55.1 7.4 14.1 11.6 19.6 12.6 22.1 20.5 54.7 15.9 37.3
Liver 3.6 1.4 2.8 1.7 5.4 2.7 5.3 3.6 3.3 2.5 4.6 2 8.9 3.9 6.4 2.6 4.7 3.3 4.1 2.5
Gallbladder 0.8 0.8 1 1.3 1.8 1.9 1.1 1.1 1.3 1.9 0.6 0.5 1.9 1.2 1.2 1 2.3 3.1 1.6 1.9
Pancreas 3.1 1.3 2.1 1.5 5 3.2 3.2 1.7 3.5 3.1 2.5 1.3 2.8 0.9 2.6 1.3 6.1 5.2 3.9 2.8
Larynx 3.3 4.5 3.8 10.5 6 14 2.1 4.3 6.6 22.3 1.4 2.5 2.7 3.6 1.4 2.9 7.9 25.9 5.3 14.8
Lung 21.3 7.6 10.3 9.2 27 19.8 9.9 7.6 30.2 33.1 6.7 3.8 13.4 7 7.3 4.6 63.9 65.8 33.3 29.3
Melanoma of skin 0.5 0 0.9 2.4 0.4 1.7 0.1 0.2 1 3.7 0.4 0.4 0.6 1.1 0.3 0.6 2.1 7.3 1.3 3.8
Kaposi sarcoma 0.1 0.3 0.2 0.5 0.4 0.7 0 0 0.3 1 0.1 0.3 0.6 1 0.4 0.7 0.5 1.2 0.3 0.8
Prostate 13.5 14.6 12.6 34.8 15.3 34.1 14.5 28.2 37.2 129.7 10.2 14.7 13.2 10.4 9.5 15.5 40.6 117.2 24.9 62.2
Testis 1.3 6.4 1.7 7.6 1.7 10.1 0.6 4.1 2.4 15.5 0.4 2.1 0.5 4.5 0.6 3.1 3.2 18 2 10.7
Kidney 2.7 4.7 3 6.9 4.3 9.1 2.6 5.4 4.8 13.7 2.1 3 4.4 7.6 2.8 5.5 6.8 18.2 4.6 10.8
Bladder 9.6 12.7 13.2 36.8 12.3 28.3 7.1 16.2 29.1 100.6 6.7 11.4 6.7 8 5.7 11.6 28.7 88.3 19.1 51
Brain, nervous system 3.6 3.8 4.6 9.4 4.3 6.4 1.9 2.9 5 9 2.2 2.8 2.4 4 2.2 2.6 5.8 10.6 4.6 8.4
Thyroid 1.2 2.8 1.4 6.4 1.9 8 1.5 6.9 2.3 11 1 4.1 1.1 1.8 1.7 6.9 3.8 19.3 2.4 11.1
Hodgkin lymphoma 1.4 2.5 1.6 6.2 2.3 8 1.5 6.5 4.2 17.8 1.3 5.3 1.5 4.1 1.8 6.1 2.8 10.8 2.2 8
Non-Hodgkin lymphoma 4.7 6.5 5.7 10.5 5.8 10.7 7.6 18.2 14.7 31.8 6.2 9.3 5.9 9 6.5 9.4 8.3 16.5 7 13
Multiple myeloma 1.6 1.1 2 3.1 3.2 4.6 1.6 2.4 2.3 4.4 1.4 1.8 2.3 2.1 1.1 1.4 3.3 6.3 2.4 4
Leukemia 5.1 3.1 6.9 7.7 7.8 7.8 6.8 8.7 8.5 10.5 5.1 4.7 5.2 7.1 4.2 3.9 7.1 8.3 6.6 7.3
All cancers excluding
nonmelanoma skin cancer
112.8 118.8 134.7 267.8 153.3 259.3 89.8 165.6 203.9 533.1 78.6 108.1 104 123.9 85.9 130.7 257.8 557.7 181 347.6
ASR, age-standardized rates.
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Table 2. Incidence ASR (per 100,000 person-years) and 5-y prevalence (P) (proportion per 100,000) of Cancer Incidence in West Asia, Female
Bahrain Iran Jordan Kuwait Lebanon Oman Qatar Saudi Arabia Turkey Pooled
ASR P ASR P ASR P ASR P ASR P ASR P ASR P ASR P ASR P ASR P
Lip, oral cavity 1.2 0 1.8 4.7 1.2 3.4 1.3 4.1 1.5 4.4 1.7 3 1.9 0 2.1 4.3 1.5 4.3 1.6 4.3
Nasopharynx 0.2 0.8 0.4 1.4 0.8 2.1 0.6 1 0.3 1.4 0.2 0.5 0.3 1.5 0.9 2.6 0.5 1.7 0.5 1.7
Other pharynx 0 0 0.3 0.7 0.3 0.6 0 0 0.2 0.7 0.1 0.5 0 0 0.4 0.9 0.2 0.7 0.3 0.7
Esophagus 1.3 1.6 8 7.7 0.6 0.5 0.9 0.8 0.6 0.8 1.2 0.7 3 1.5 1.4 1 3 3.7 4.5 4.8
Stomach 3.1 3.5 9.7 13.2 5.3 7.2 2.1 3.8 4.7 9.1 3.9 3.8 5.6 6.8 2.4 2.9 10.9 19.1 9.2 13.7
Colorectal 11 23.7 10.5 25.2 21.2 44.8 13.3 30.9 13.5 43.4 7.6 13.4 15.5 34.3 10.8 22.5 13.1 38.2 12.1 30.9
Liver 3.4 1.3 2.1 1.3 3 1.4 1.9 1.1 1.9 1.6 2.8 1.1 5 1.8 2.8 1.4 1.8 1.4 2.1 1.4
Gallbladder 0.9 0 1.4 1.6 3.1 3.3 1.3 1.4 1.8 3 0.8 0.6 2.7 1.8 2.8 2.6 1.3 1.9 1.6 1.9
Pancreas 3 1.3 1.6 1.2 3.4 2.2 2.7 1.3 2.7 2.5 1.8 1 0.6 0.6 2.2 1.2 3.1 2.8 2.4 1.9
Larynx 0 0 0.6 1.7 0.7 1.9 0.5 1 1.2 4 0.3 1.2 0 0 0.2 0.4 0.5 1.7 0.5 1.6
Lung 8.5 4.3 5 4.5 4.1 3.1 4.8 3.6 11 13.3 2.8 1.7 4.1 3.8 2.7 2 8.8 10 6.7 6.5
Melanoma of skin 0 0 0.7 1.8 0.6 1.7 0 0 1.2 4.8 0.4 0 0.2 0.9 0.3 0.9 2.1 7.5 1.3 4
Kaposi sarcoma 0 0 0.1 0.2 0.2 0.3 0 0 0.1 0.2 0.2 0.2 0 0 0.2 0.3 0.2 0.5 0.1 0.4
Breast 42.5 168.1 28.1 118.1 61 212.9 46.7 164.4 78.7 391.7 26 82.3 46.1 183.8 29.5 113.8 39.1 187 35.4 154.3
Cervix uteri 5.9 17.1 2.8 9.1 2.4 7.3 4 15.5 4.6 18.6 5.3 12.6 5.1 18.6 2.7 8.1 4.3 16.7 3.5 12.3
Corpus uteri 4.7 14.1 2.5 10.1 5.2 16.7 7.5 20.4 7.7 39.4 3.8 10.1 5.7 16.3 5.8 18.2 10.1 49.9 6.5 27.7
Ovary 4.4 9.6 4.8 14.1 5.4 13 4.7 13.1 7.5 25.6 3.3 7.5 4.6 13 3.4 8.4 6.3 20.8 5.4 16.1
Kidney 2.5 5.6 2.1 4.9 2 4 1.5 2.9 1.8 5.7 2.1 2.5 1.5 5.3 1.8 3.8 4.4 12.6 3.1 7.7
Bladder 2.1 4.5 3.4 9.4 1.8 4.2 2.7 5.8 6.1 24 2.3 4.4 1.9 1.8 1.2 2.8 3.5 12 3.3 9.6
Brain, nervous system 1.8 3.7 3.8 7.4 3.4 5.8 1.5 2.5 3.1 5.9 1.7 2 2.6 5.3 1.9 2.5 6.4 12.1 4.6 8.4
Thyroid 4.1 17.6 4 19.9 7.2 34 6.5 32.4 6.3 34.9 5.2 25.1 6.5 33.4 7.5 38.7 17.8 95.5 10.3 52.7
Hodgkin lymphoma 0.6 0.8 1.1 4.3 2.3 10.3 1.3 7.9 3.2 13.2 1.5 3.6 1.2 8 1.4 4.8 1.4 5.2 1.4 5.1
Non-Hodgkin lymphoma 3.5 5.3 3.8 7 6 10.3 3.4 9 11.5 26.5 5.7 8.1 7 15.4 6.1 9.6 5.5 11.4 5.1 9.6
Multiple myeloma 1.6 1.9 1.2 2.2 1.9 2.6 1.3 2.4 2.1 4.7 1 1.2 1 0 0.9 1.2 2.6 5.4 1.9 3.4
Leukemia 4.6 5.1 4.7 5.6 4.3 4.8 6.2 8.4 5.6 7.4 4.7 3.9 3.8 5.9 3.5 3.9 4.7 5.3 4.6 5.3
All cancers excluding
nonmelanoma skin cancer
121.9 308 120.1 312.8 157.8 420.5 123.3 348 192.8 725.7 92.4 199.6 134.5 378 102.8 274.7 161.6 549.5 139.2 412.9
ASR, age-standardized rates.
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Table 3. Incidence ASR (per 100,000 person-years) and CR (0-74; %) of Cancer Mortality in West Asia, Male
Bahrain Iran Jordan Kuwait Lebanon Oman Qatar
Saudi
Arabia Turkey Pooled
ASR CR ASR CR ASR CR ASR CR ASR CR ASR CR ASR CR ASR CR ASR CR ASR CR
Lip, oral cavity 0.5 0.06 0.7 0.08 0.7 0.05 0.3 0.03 0.8 0.09 0.6 0.07 0.5 0.06 0.6 0.07 0.9 0.11 0.8 0.09
Nasopharynx 0.1 0.02 0.4 0.05 0.7 0.07 0.1 0.02 0.5 0.05 0.3 0.04 0.6 0.12 0.9 0.11 0.9 0.1 0.7 0.08
Other pharynx 0.5 0.08 0.3 0.03 0.3 0.02 0 0 0.3 0.04 0.4 0.05 0.6 0.1 0.3 0.03 0.7 0.08 0.4 0.05
Esophagus 1.4 0.06 8.2 0.95 1.1 0.16 0.9 0.1 0.9 0.11 1.8 0.21 1.8 0.15 1.4 0.14 4 0.47 5.2 0.59
Stomach 3.9 0.45 17.3 1.93 5.6 0.63 1.5 0.19 5.2 0.59 5.8 0.74 5.4 0.75 3.3 0.38 15.5 1.83 14.2 1.61
Colorectal 3.2 0.6 6.9 0.79 17.9 2.1 5.6 0.71 10.5 1.17 4.8 0.49 6.6 0.83 7.3 0.89 12.6 1.47 9.6 1.13
Liver 5.6 0.96 2.6 0.3 5.2 0.65 5.1 0.67 3.1 0.35 4.6 0.49 9.5 1.29 6.2 0.77 4.5 0.55 3.9 0.48
Gallbladder 0 0 0.9 0.11 1.7 0.21 0.4 0.03 1.3 0.15 0.6 0.06 1.8 0.24 1.1 0.13 2.2 0.27 1.5 0.18
Pancreas 3 0.29 2 0.25 5 0.59 3.1 0.45 3.3 0.41 2.7 0.22 2.8 0.37 2.6 0.34 6 0.73 3.8 0.48
Larynx 1.8 0.17 1.5 0.19 2.5 0.29 1 0.19 2.4 0.29 0.5 0.06 0.8 0.04 0.5 0.07 3.3 0.41 2.2 0.27
Lung 16.5 1.8 9.1 1.05 24.1 2.85 8.3 1.09 26.9 3.21 6.1 0.7 12.7 1.89 6.7 0.85 57.5 6.91 29.9 3.69
Melanoma of skin 0.1 0.02 0.3 0.03 0.2 0.01 0 0 0.3 0.02 0.2 0.04 0 0 0.1 0.01 0.9 0.11 0.5 0.06
Kaposi sarcoma 0 0 0.1 0.01 0.1 0.01 0 0 0.1 0.01 0.1 0.01 0.5 0 0.2 0.02 0.2 0.02 0.2 0.02
Prostate 6.5 0.6 6.2 0.49 8.3 0.78 3 0.27 17.1 1.38 6.3 0.57 6 0.61 4.8 0.47 22.8 2.24 13.2 1.3
Testis 0 0 0.7 0.06 0.8 0.06 0 0 0.7 0.04 0.2 0.01 0 0 0.2 0.02 1.3 0.11 0.8 0.07
Kidney 1.5 0.19 2 0.23 2.9 0.32 1.2 0.16 3 0.34 1.5 0.18 2.8 0.38 1.8 0.2 4.7 0.54 3.1 0.36
Bladder 3.9 0.4 5.5 0.59 5.5 0.6 2.5 0.3 11 1.18 3.4 0.42 2.4 0.25 2.3 0.27 12.8 1.51 8.3 0.97
Brain, nervous system 1.4 0.14 3 0.31 2.7 0.29 2.3 0.3 2.8 0.29 1.5 0.17 1.6 0.26 1.2 0.12 3.6 0.37 2.9 0.31
Thyroid 0 0 0.5 0.05 0.8 0.08 0 0 0.6 0.05 0.6 0.13 0.4 0.1 0.9 0.1 0.8 0.11 0.7 0.08
Hodgkin lymphoma 0.1 0.01 0.8 0.08 1.4 0.15 0 0 1.9 0.2 0.7 0.08 0.3 0.03 0.9 0.09 1.5 0.16 1.1 0.12
Non-Hodgkin lymphoma 0.3 0.02 3.6 0.39 3.8 0.43 2.1 0.25 8.6 0.96 4.5 0.56 4.2 0.6 4.3 0.48 5.3 0.6 4.5 0.5
Multiple myeloma 0.7 0.03 1.6 0.2 2.6 0.32 0.6 0.07 1.7 0.21 1.3 0.13 2.2 0.39 0.9 0.12 2.6 0.33 1.9 0.25
Leukemia 2.6 0.22 5.4 0.56 6.5 0.67 3 0.31 6.3 0.62 4.3 0.35 3.7 0.27 3.1 0.3 5.8 0.58 5.3 0.53
All cancers excluding
nonmelanoma skin cancer
60.9 6.61 90.4 9.38 105.2 11.25 46.4 5.69 119.5 12.05 57.8 6.2 71.8 8.79 56.8 6.33 179 18.93 123.6 13.32
ASR, age-standardized rates; CR, cumulative risk.
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Table 4. Incidence ASR (per 100,000 person-years) and CR (0-74; %) of Cancer Mortality in West Asia, Female
Bahrain Iran Jordan Kuwait Lebanon Oman Qatar
Saudi
Arabia Turkey Pooled
ASR CR ASR CR ASR CR ASR CR ASR CR ASR CR ASR CR ASR CR ASR CR ASR CR
Lip, oral cavity 0.2 0.03 0.6 0.07 0.4 0.04 0.7 0.08 0.4 0.05 0.1 0 0 0 0.6 0.07 0.5 0.06 0.5 0.06
Nasopharynx 0 0 0.2 0.03 0.5 0.06 0 0 0.1 0.01 0.1 0.01 0 0 0.5 0.05 0.3 0.03 0.3 0.03
Other pharynx 0 0 0.2 0.03 0.3 0.02 0.2 0 0.2 0.02 0.1 0 0 0 0.3 0.03 0.2 0.02 0.2 0.02
Esophagus 0.2 0.03 7.4 0.88 0.6 0.07 1.2 0.07 0.6 0.04 1.2 0.14 3 0.37 1.3 0.15 2.7 0.31 4.2 0.49
Stomach 2.9 0.24 8.3 0.94 4.5 0.5 1.7 0.18 3.8 0.41 3.4 0.41 4.5 0.58 2.1 0.23 9.3 1.07 7.8 0.9
Colorectal 5 0.61 6.3 0.74 13 1.5 8.6 0.93 7.4 0.83 4.7 0.55 9.7 1.11 6.1 0.71 7.8 0.89 7.2 0.83
Liver 3.4 0.44 2 0.22 2.9 0.34 4.2 0.54 1.7 0.19 2.8 0.31 5 0.72 2.7 0.33 1.7 0.19 2 0.22
Gallbladder 0.5 0.12 1.3 0.16 2.8 0.32 1.4 0.19 1.6 0.19 0.8 0.09 2.7 0.48 2.7 0.32 1.3 0.15 1.5 0.17
Pancreas 2.4 0.31 1.6 0.18 3.3 0.43 3.9 0.47 2.6 0.34 1.8 0.16 0.6 0.07 2.2 0.27 2.9 0.36 2.4 0.29
Larynx 0 0 0.2 0.03 0.3 0.04 0.1 0 0.4 0.05 0 0 0 0 0.1 0.01 0.2 0.02 0.2 0.02
Lung 7.6 0.98 4.5 0.52 3.7 0.44 3.4 0.32 9.6 1.13 2.8 0.33 4.1 0.46 2.5 0.3 7.8 0.93 6 0.71
Melanoma of skin 0 0 0.3 0.03 0.3 0.03 0 0 0.4 0.03 0 0 0 0 0.1 0.01 0.8 0.09 0.5 0.06
Kaposi sarcoma 0 0 0 0 0.1 0.01 0 0 0 0.01 0 0 0 0 0 0.01 0.1 0.01 0.1 0.01
Breast 11.1 1.19 9.9 1.08 21.8 2.44 17.3 2.13 24 2.63 9.5 1.06 11.2 1.26 9.1 1 13.4 1.47 12.1 1.34
Cervix uteri 1.9 0.27 1.2 0.14 1 0.1 2.1 0.31 1.7 0.19 2.5 0.31 2.4 0.28 1.1 0.13 1.7 0.2 1.4 0.17
Corpus uteri 1.3 0.25 0.6 0.08 1.3 0.17 3.8 0.47 1.6 0.19 0.9 0.12 1 0 1.3 0.17 2.6 0.33 1.7 0.21
Ovary 2.4 0.22 3.4 0.4 3.8 0.47 3.3 0.47 4.7 0.54 2.7 0.33 3.4 0.44 2.5 0.29 4.2 0.49 3.7 0.44
Kidney 0.5 0.06 1.4 0.15 1.4 0.18 0.6 0.06 1.1 0.11 1.5 0.2 0.8 0.08 1.1 0.11 2.9 0.33 2.1 0.23
Bladder 0.8 0 1.4 0.14 0.9 0.09 1.6 0.11 2.4 0.23 1.2 0.14 0 0 0.5 0.05 1.5 0.17 1.4 0.15
Brain, nervous system 0.6 0.07 2.5 0.26 2.2 0.22 2.6 0.34 1.8 0.19 1.4 0.13 1 0 1 0.1 3.9 0.4 2.9 0.3
Thyroid 1.1 0.09 1.4 0.16 2.9 0.31 1 0.08 1.4 0.14 2.3 0.11 2.8 0.23 2.5 0.3 1.8 0.24 1.7 0.21
Hodgkin lymphoma 0 0 0.6 0.06 1.3 0.12 0.1 0 1.2 0.13 0.9 0.08 0.2 0.01 0.7 0.06 0.7 0.07 0.7 0.07
Non-Hodgkin lymphoma 1 0.15 2.4 0.27 4 0.45 1.8 0.22 6.6 0.74 3.9 0.41 5 0.63 3.8 0.43 3.4 0.37 3.1 0.35
Multiple myeloma 1.5 0.21 1 0.12 1.4 0.18 0.7 0.07 1.6 0.18 0.9 0.1 1 0.12 0.7 0.07 2.1 0.25 1.5 0.18
Leukemia 1.5 0.2 3.8 0.37 3.6 0.36 4.2 0.5 4.1 0.4 4.1 0.35 2.8 0.3 2.5 0.24 3.6 0.35 3.6 0.35
All cancers excluding nonmelanoma skin cancer 50.6 5.87 72.7 7.81 85.5 9.27 69.3 7.82 89.6 9.37 54 5.67 66.6 7.38 52.7 5.81 86.7 9.43 77.7 8.45
ASR, age-standardized rates; CR, cumulative risk.
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Figure 2. Incidence age-standardized rates (ASR; per 100,000 person-year) of cancers in West Asian countries. (Figure in each box
indicates the ASR; size of bubbles represents the magnitude of ASRs; solid bubbles indicate men and dotted bobbles indicate women.)
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Nine countries and 6 regional registries were included
(Fig. 1). The ASRs and 5-year prevalence of cancers are
presented for men and women of West Asian countries
in Tables 1 and 2, respectively. The ASRs and cumula-
tive risk for cancer mortality are shown in Tables 3 and 4
for men and women, respectively.
Cancers of lung (ASR, 33.3), prostate (24.9), bladder
(19.1), stomach (16.5), and colorectal (15.9) were the most
common malignancies in men. The most common can-
cers of women were those of the breast (35.4), colorectal
(12.1), thyroid (10.3), stomach (9.2), and lung (6.7).
Figure 2 shows the ASR of cancers in West Asia.
Spearman’s correlation test suggested a significant posi-
tive correlation between the rate of male cancers and the
geographic latitude (Spearman’s r ¼ 0.87; P < .001).
The correlation was not significant for female cancers
(Spearman’s r ¼ 0.39; P ¼ .19).
The incidence of gastric cancer also was significantly
correlated with the geographic latitude in both men
(Spearman’s r ¼ 0.82; P ¼ .001) and women (Spear-
man’s r ¼ 0.79; P ¼ .001; Fig. 3).
Figure 4 shows the distribution of esophageal cancer
in West Asian countries. As shown in Figure 5, weFigure 3. Incidence age-standardized rates (ASR; per 100,000 perso
box indicates the ASR; size of bubbles represents the magnitude of
women.)found significant positive correlation between the ASR of
lung cancer in men and the geographic latitude of
countries (Spearman’s r ¼ 0.75; P ¼ .003). The distri-
bution of breast and colorectal cancers (CRCs) are
shown in Figures 6 and 7, respectively. High incidence
rates of bladder (Fig. 8) and prostate (Fig. 9) cancers were
found in Lebanon and Turkey.DISCUSSION
Using data from Globocan-2012, we found the most
common cancers in West Asia to be malignancies of
lung, prostate, bladder, stomach, and colorectal in men
and breast, colorectal, stomach, thyroid, and lung in
women. A noteworthy observation is the striking differ-
ences in cancer mortality and incidence by geographic
location.
All Cancers
The incidence of male cancers was considerably higher in
the northern part of this region, consisting of Turkey,
Lebanon, Jordan, and northern Iran compared with the
southern countries comprising Bahrain, Kuwait, Oman,
Qatar, Saudi Arabia, and southern Iran. This may suggestn-year) of gastric cancer in West Asian countries. (Figure in each
ASRs; solid bubbles indicate men and dotted bobbles indicate
Figure 4. Incidence age-standardized rates (ASR; per 100,000 person-year) of esophageal cancer inWest Asian countries. (Figure in each
box indicates the ASR; size of bubbles represents the magnitude of ASRs; solid bubbles indicate men and dotted bobbles indicate women.)
Anna l s o f G l o b a l Hea l t h 353higher prevalence of cancer risk factors including smok-
ing,5,6 and obesity.7-9 The most common cancers differed
by country. Lung cancer was the leading malignancy in
men in Bahrain, Qatar, and Turkey, whereas CRCwas the
most common malignancy in Saudi and Jordanian men.
Cancer of the stomach ranked highest among Iranian
men. Prostate cancer was the most common in Kuwait,
Lebanon, and Oman. Considering these differences,
cancer control programs must be tailored to the most
common types of cancers in each country.
Gastric Cancer
Gastric cancer does not occur equitably over West Asia,
afflicting northern countries of Iran and Turkey to a
greater extent compared with others. It is the second and
the sixth most incidence malignancy in Iran and Turkey,
respectively, whereas its incidence rank is relatively lower
in other countries of this region, ranging from seventh in
Qatar to 14th in Kuwait. Even within Iran, a striking
difference is observed by geography where northern
provinces experience a 6-fold incidence rate in compari-
son to the southern regions.10
Helicobacter pylori is the established class I risk factor
for development of gastric cancer.11 The infection is
contracted at very young age and involves increasing
fractions of a population with advancing age. TheFigure 5. Incidence age-standardized rates (ASR; per 100,000 person
indicates the ASR; size of bubbles represents the magnitude of ASRs; sprevalence of H pylori reported from West Asian coun-
tries varies by the study population and diagnostic
method used; nevertheless, according to data from the
“WHO STEPwise approach to Surveillance of risk fac-
tors (STEPS) projects, all these countries indicate high
rates of H pylori infection, resembling most other devel-
oping countries12-16 (Table 5). Therefore, despite its
status as sine qua non, factors other than H pylori seem to
affect the disparity in gastric cancer incidence across
regions.17
Numerous studies have attempted to identify the
natural course of gastric cancer and the associated fac-
tors. Tobacco use,18,19 excessive salt intake,20,21 deficient
consumption of fruit and vegetables,22,23 and familial
factors24 are among those incriminated in this process.
The variety of ethnicities and subcultures inhabiting this
region of the world display an array of dietary and
tobacco-related habits, which may account for the
discrepancy in incidence of gastric cancer. Opium (an
illicit drug used frequently in certain regions of West
Asia) has been shown to be correlated with the occur-
rence of gastric cancer,25 especially in light of a recent
study that demonstrated that opium and hookah (a to-
bacco product popular in West Asian countries) are
associated with not only an increased incidence of gastric
cancer, but also its precancerous lesions.26-year) of lung cancer in West Asian countries. (Figure in each box
olid bubbles indicate men and dotted bobbles indicate women.)
Figure 6. Incidence age-standardized rates (ASR; per 100,000 person-year) of breast cancer in West Asian countries, women. (Figure in
each box indicates the ASR; size of bubbles represents the magnitude of ASRs).
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The incidence rate of esophageal cancer was considerably
high in the northeastern part of West Asia. This area
(northern Iran) is located on the western edge of the
Asian belt of upper gastrointestinal (GI) cancers,
extending to north-central China in the East. An
extremely high rate of esophageal cancer in this area was
first reported in 1972.3,4 Although recent reports suggest
a decreasing trend for this cancer, it remains the top-
ranking malignancy in this region.27,28 According to
the results of a large cohort study,29 the most important
risk factors for esophageal cancer in this area include
drinking hot tea,30 low socioeconomic status,31 genetic
susceptibility,32,33 dietary habits,34 opium and tobacco
consumption,35 and poor oral health.36 Additionally,
ecological studies from this region37-39 suggested corre-
lations between environmental factors and esophageal
cancer. Esophageal cancer is a multifactorial condition
and may not be successfully controlled by primary pre-
vention (i.e., avoiding all possible risk factors). Therefore,
it is recommended that screening programs be con-
ducted in this area as well as in other high-risk
regions.40,41
Figures 3 and 4 suggest a south to north gradient of
upper GI (esophageal and gastric) cancers inWest Asia. InFigure 7. Incidence age-standardized rates (ASR; per 100,000 person
box indicates the ASR; size of bubbles represents the magnitude of
women.)other words, the incidence of upper GI cancers increases
as we move northward in this region. This may be
explained by the fact that in the north, the weather is cold
and using biomass as the primary fuel for cooking and
heating in poorly ventilated houses, may produce consid-
erable amounts of polycyclic aromatic hydrocarbons
(PAH)—a known risk factor for upper GI cancers.42-44 It
may be beneficial to take this point into consideration
when planning for cancer prevention in this part of the
world, as well as in other high-risk areas. Another
declining trend is found in the incidence of upper
GI cancer, starting in the northern areas of Iran and
moving westward to reach the European borders of Turkey
(Figs. 3 and 4).
Lung Cancer
We found a very high incidence rate of lung cancer in
men in Turkey, Lebanon, and Jordan, located in the
northwestern part of the study area. This may be partly
explained by the high prevalence of smoking in these
countries5,6 (Table 5). Despite many local and national
tobacco-control efforts during the recent decade, the
prevalence of smoking remains high in Turkey.45
Implementation of comprehensive tobacco-control pro-
grams may decrease the prevalence of this risk factor and-year) of colorectal cancer in West Asian countries. (Figure in each
ASRs; solid bubbles indicate men and dotted bobbles indicate
Figure 8. Incidence age-standardized rates (ASR; per 100,000 person-year) of bladder cancer in West Asian countries. (Figure in each
box indicates the ASR; size of bubbles represents the magnitude of ASRs; solid bubbles indicate men and dotted bobbles indicate
women.)
Anna l s o f G l o b a l Hea l t h 355consequently help to decrease the burden of lung cancer
in such high-risk areas.
Contrary to the upper GI cancer, the gradient of
lung cancer rises from east to west (Fig. 5). In other
words, as we move from Golestan, Iran in the East to
Edirne, Turkey in the West, the incidence of upper GI
cancer decreases, while the incidence of lung cancer
increases. This interesting trend may warrant further
international studies on these types of cancer in this
region.
Breast Cancer
The incidence of breast cancer was high in some Arabian
countries including Qatar, Kuwait, and Bahrain with the
highest rates in Jordan and Lebanon. High prevalence of
obesity, a risk factor for breast cancer, was reported in
these countries7,9,46 (Table 5). Reports from other
countries such as Iran47-49 also have shown that special
consideration should be given to breast cancer in this
region. Probable changes in the prevalence of risk factors
of breast cancer including age at menarche, age at first
pregnancy, number of pregnancies, duration of breast-
feeding, and lifestyle and environmental exposures mayFigure 9. Incidence age-standardized rates (ASR; per 100,000 person
each box indicates the ASR; size of bubbles represents the magnitudeinfluence the epidemiology of this common malignancy
and increase its incidence and mortality rates and
consequently its burden in this region in near future.
Further studies are warranted to determine the risk fac-
tors for breast cancer, especially modifiable or prevent-
able ones in West Asian countries.
Colorectal Cancer
High incidence of CRC was found in Jordan, Lebanon,
and Turkey, located in the northwestern part of this re-
gion. Although recent reports suggest an increasing trend
in the incidence rate of CRC in Iran,27,28 it is still
considered a low-risk area.50,51 High prevalence of
obesity7,9 and lifestyle modifications including changes in
physical activity and dietary habits52-54 may partly explain
the high incidence of CRC in parts of this region
(Table 5). High CRC incidence rates were reported in
young populations from parts of this region.50,55 This
may be explained by changes in diet and lifestyle favoring
a Westernized pattern in the younger generation of these
areas. Any effort in promoting healthier lifestyle in these
populations may help to decrease the burden of this
disease in such high-risk areas.-year) of prostate cancer in West Asian countries, men (Figure in
of ASRs).
Table 5. Prevalence (%) of Risk Factors for Cancers in West Asian Countries According to Most Recent Data of the STEPS*
Survey on Chronic Disease Risk Factors for Each Country
Risk Factor Bahrain Iran Jordan Kuwait Qatar Saudi Arabia Turkey
Smoking
Total 19.9 14.76 29.0 20.6 14.7 - 35.6
Cigarettes 13.8 12.27 28.3 17.7 11.8 17.6 32.4
Hookah 8.4 2.53 - 2.0 - 2.9 -
Overweight/obesity 69.2% 46.0 67.4 75.4 70.1 66.2†
71.4‡
54.3
Physical inactivity 28.4% 35.22 5.2 64.7 45.9 67.7 34.3
Low fruit/vegetable intake - 87.2 14.2 81.0 91.1 97.9†
99.2‡
81.4
*The WHO STEPwise approach to Surveillance of risk factors (STEPS).
†Men.
‡Women.
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The incidence rates of bladder (in men) and prostate
cancers were higher in the northwestern part of West
Asia (Turkey and Lebanon). Smoking is proposed as
the most important risk factor for bladder cancer in
these countries.56,57 Occupational exposure (e.g., to
diesel) also has been suggested as a risk factor for this
cancer.56 Obesity and dietary habits have been pro-
posed to play a role in the pathogenesis of prostate
cancer58,59 (Table 5). Therefore, controlling these risk
factors must be considered in preventive programs in
these areas.Altitude and Cancer
Our results showed higher rates of cancers especially
gastric and lung malignancies in countries and regions
located in higher latitudes. Higher rates of mortality from
cancers of the stomach, pharynx, and larynx in residents of
high-altitude areas have been reported.60 The results from
a study in Latin America showed a positive association
between gastric cancer risk and altitude.61 The study’s
findings suggested altitude as a probable surrogate for ge-
netic, dietary, and environmental risk factors for gastric
cancer.
The geographical characteristics of West Asia sug-
gest a positive correlation between latitude and altitude.
In other words, countries and areas in higher latitude of
this region also may have higher altitude. So, our
finding on the correlation between cancer rates and
latitude might be confounded by altitude. Further
individual-based studies are warranted to clarify this
point.
A major limitation of the present study is lack of
high-quality data from some West Asian countries. The
Globocan-2012 estimation of cancer incidence in these
countries was made using cancer data from neighboring
countries. This is mainly due to the absence of well-
designed cancer registries in these countries.CONCLUSION
We found considerable differences in the incidence and
mortality of the most common cancers among West
Asian countries. Cancer control programs must be
tailored to the most common types of cancers in each
country. As the first step of cancer control programs, it is
recommended to establish well-structured population-
based cancer registries in all these countries.References
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